These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 15142198)

  • 21. Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study.
    Di Girolamo G; Keller GA; de Los Santos AR; Schere D; Gonzalez CD
    Clin Ther; 2008 Nov; 30(11):2015-23. PubMed ID: 19108789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-Aminosalicylic acid derivatives. Clinical and pharmaceutical evaluation.
    Christensen LA; Jacobsen BA
    Neth J Med; 1989 Jun; 35 Suppl 1():S3-10. PubMed ID: 2702310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediate-and extended-release formulations in healthy subjects.
    Marier JF; Ducharme MP; DiMarco M; Di Spirito M; Morelli G; Tippabhotla SK; Badri N; Rampal A; Monif T
    Clin Ther; 2006 Dec; 28(12):2070-80. PubMed ID: 17296463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
    Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
    Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is once-daily mesalazine equivalent to the currently used twice-daily regimen? A study performed in 30 healthy volunteers.
    Gandia P; Idier I; Houin G
    J Clin Pharmacol; 2007 Mar; 47(3):334-42. PubMed ID: 17322145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
    Loftus EV; Kane SV; Bjorkman D
    Aliment Pharmacol Ther; 2004 Jan; 19(2):179-89. PubMed ID: 14723609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioavailability of two oral formulations of loratadine 20 mg with concomitant ketoconazole: an open-label, randomized, two-period crossover comparison in healthy Mexican adult volunteers.
    Piñeyro-López A; Pineyro-Garza E; Torres-Alanís O; Reyes-Araiza R; Gómez Silva M; Wacksman N; Lujàn Rangel R; de Lago A; Trejo D; Gonzàlez-de la Parra M; Namur S
    Clin Ther; 2006 Jan; 28(1):110-5. PubMed ID: 16490584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers.
    Darwish M; Chang S; Hellriegel ET
    Clin Ther; 2009 Jan; 31(1):108-14. PubMed ID: 19243711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of ulcerative colitis with balsalazide: response to editorial by Drs. Farrell and Peppercorn and letter to the editor by Dr. Hanauer.
    Johnson LK; Pruitt RE; Green JR
    Am J Gastroenterol; 2003 Jan; 98(1):216-9. PubMed ID: 12526969
    [No Abstract]   [Full Text] [Related]  

  • 32. The mesalamine wars heat up-enter balsalazide.
    Cohen RD
    Gastroenterology; 2003 Feb; 124(2):574-5. PubMed ID: 12557164
    [No Abstract]   [Full Text] [Related]  

  • 33. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A clinical trial on absorption and N-acetylation of oral and rectal mesalazine.
    Dilger K; Trenk D; Rössle M; Cap M; Zähringer A; Wacheck V; Remmler C; Cascorbi I; Kreisel W; Novacek G
    Eur J Clin Invest; 2007 Jul; 37(7):558-65. PubMed ID: 17576207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral balsalazide (Colazal) for ulcerative colitis.
    Med Lett Drugs Ther; 2001 Jul; 43(1109):62-3. PubMed ID: 11468602
    [No Abstract]   [Full Text] [Related]  

  • 36. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
    Christensen LA
    Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-dose pharmacokinetic study of rapidly dispersing diclofenac potassium formulations in healthy volunteers.
    Lissy M; Stiff DD; Kowalski MM; Moore KA
    Curr Med Res Opin; 2009 Oct; 25(10):2423-8. PubMed ID: 19663688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioavailability of two oral formulations of a single dose of levofloxacin 500 mg: an open-label, randomized, two-period crossover comparison in healthy Mexican volunteers.
    Galan-Herrera JF; Poo JL; Rosales-Sanchez O; Fuentes-Fuentes E; Cariño L; Burke-Fraga V; Namur S; Parra MG
    Clin Ther; 2009 Aug; 31(8):1796-803. PubMed ID: 19808138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial.
    Portolés A; Calvo A; Terleira A; Laredo L; Resplandy G; Gorostiaga C; Moreno A
    J Clin Pharmacol; 2006 Oct; 46(10):1195-203. PubMed ID: 16988209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: an open-label, randomized, single-dose, two-way crossover study.
    Dos Reis Serra CH; Mori Koono EE; Kano EK; Schramm SG; Armando YP; Porta V
    Clin Ther; 2008 May; 30(5):902-8. PubMed ID: 18555936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.